- Home
- MEGL vs BGMS Comparison
MEGL vs BGMS Comparison
Compare MEGL & BGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | MEGL | BGMS |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | Hong Kong | Malaysia |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 5.0M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | MEGL | BGMS |
|---|---|---|
| Price | $1.05 | $0.92 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.9K | ★ 26.9K |
| Earning Date | 10-17-2025 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $137.21 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $0.73 |
| 52 Week High | $2.62 | $6.70 |
Technical Indicators
Market Signals| Indicator | MEGL | BGMS |
|---|---|---|
| Relative Strength Index (RSI) | 50.21 | 41.08 |
| Support Level | $0.88 | $0.74 |
| Resistance Level | $1.05 | $1.12 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 56.00 | 58.51 |
Price Performance
Historical ComparisonAbout MEGL Magic Empire Global Limited
Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The companys offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.
About BGMS Bio Green Med Solution Inc.
Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.